Published in Cancer Res on June 01, 1999
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol (2001) 3.55
Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A (2009) 2.80
Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol (2013) 2.01
Chemical modulation of memory formation in larval zebrafish. Proc Natl Acad Sci U S A (2011) 1.27
Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem (2008) 1.26
Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chemother (2004) 1.21
GSK-3β: A Bifunctional Role in Cell Death Pathways. Int J Cell Biol (2012) 1.21
Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles. RNA (2004) 1.15
Glycogen synthase kinase-3 regulates IGFBP-1 gene transcription through the thymine-rich insulin response element. BMC Mol Biol (2004) 1.05
Selectivity and potency of cyclin-dependent kinase inhibitors. AAPS J (2006) 1.04
Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. J Biol Inorg Chem (2010) 1.03
Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel) (2015) 0.99
Mechanism targeted discovery of antitumor marine natural products. Curr Med Chem (2004) 0.95
Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Res Ther (2010) 0.92
Proliferation rate of somatic cells affects reprogramming efficiency. J Biol Chem (2013) 0.92
Human cytomegaloviruses expressing yellow fluorescent fusion proteins--characterization and use in antiviral screening. PLoS One (2010) 0.89
Ruthenium- and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity. Organometallics (2010) 0.89
Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation. Organometallics (2013) 0.86
Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. J Inorg Biochem (2012) 0.86
Cell cycle regulation to repair the infarcted myocardium. Heart Fail Rev (2003) 0.84
Genomics: applications in mechanism elucidation. Adv Drug Deliv Rev (2008) 0.81
High-throughput screening reveals alsterpaullone, 2-cyanoethyl as a potent p27Kip1 transcriptional inhibitor. PLoS One (2014) 0.81
Ruthenium- and osmium-arene complexes of 8-substituted indolo[3,2-c]quinolines: Synthesis, X-ray diffraction structures, spectroscopic properties, and antiproliferative activity. Inorganica Chim Acta (2012) 0.79
Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus. Antiviral Res (2012) 0.79
10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A. J Med Chem (2015) 0.78
Alsterpaullone, a Cyclin-Dependent Kinase Inhibitor, Mediated Toxicity in HeLa Cells through Apoptosis-Inducing Effect. J Anal Methods Chem (2013) 0.77
Dicopper(II) and dizinc(II) complexes with nonsymmetric dinucleating ligands based on indolo[3,2-c]quinolines: synthesis, structure, cytotoxicity, and intracellular distribution. Inorg Chem (2013) 0.76
Identification of compounds that modulate retinol signaling using a cell-based qHTS assay. Toxicol In Vitro (2016) 0.75
Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5. J Mol Model (2013) 0.75
The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis. Biochem Biophys Rep (2015) 0.75
The choice of atomic charges calculation scheme in 3D-QSAR modelling of GSK-3β inhibition by paullones. Dokl Biochem Biophys (2010) 0.75
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J Biol Chem (1994) 5.67
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer (2001) 5.58
Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res (1999) 5.35
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
cdc2 is a component of the M phase-specific histone H1 kinase: evidence for identity with MPF. Cell (1988) 4.12
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol (2001) 3.55
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (1998) 3.53
Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature (1999) 3.50
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem (2000) 3.49
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem (2000) 3.13
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem (2001) 2.79
Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol (1999) 2.78
Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem (1997) 2.65
Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst (2000) 2.62
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst (1996) 2.39
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst (1998) 2.31
Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem (2000) 2.27
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res (2001) 2.25
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res (1996) 2.24
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A (2000) 2.20
Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A (1986) 1.96
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem (2000) 1.93
dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line. J Biol Chem (1993) 1.90
The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des (1997) 1.89
Activation of M-phase-specific histone H1 kinase by modification of the phosphorylation of its p34cdc2 and cyclin components. Genes Dev (1990) 1.86
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol (1998) 1.80
Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem Biol (2000) 1.75
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res (2001) 1.65
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines. Oncogene Res (1988) 1.53
ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem (1999) 1.52
A role for ferrous ion and oxygen in the degradation of DNA by bleomycin. Biochem Biophys Res Commun (1976) 1.52
Properties and products of the degradation of DNA by bleomycin and iron(II). Biochemistry (1978) 1.47
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J Med Chem (1999) 1.47
BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem (1993) 1.47
Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun (1994) 1.47
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst (2000) 1.46
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton. J Natl Cancer Inst (1995) 1.44
L-myc cooperates with ras to transform primary rat embryo fibroblasts. Mol Cell Biol (1988) 1.43
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol (2001) 1.41
Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res (1999) 1.40
Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol (2001) 1.40
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene (2008) 1.39
Pfnek-1, a NIMA-related kinase from the human malaria parasite Plasmodium falciparum Biochemical properties and possible involvement in MAPK regulation. Eur J Biochem (2001) 1.37
Absence of Toll-like receptor 4 explains endotoxin hyporesponsiveness in human intestinal epithelium. J Pediatr Gastroenterol Nutr (2001) 1.35
Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins (1995) 1.35
In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Br J Cancer (2002) 1.34
Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition. J Biol Chem (1996) 1.33
The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp Cell Res (1998) 1.32
Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood (1998) 1.31
Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry (1978) 1.31
UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. J Biol Chem (1998) 1.30
Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia (2002) 1.29
Roscovitine, a novel cyclin-dependent kinase inhibitor, characterizes restriction point and G2/M transition in tobacco BY-2 cell suspension. Plant J (1997) 1.28
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res (1998) 1.28
Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem (1997) 1.28
Activation of myelin basic protein kinases during echinoderm oocyte maturation and egg fertilization. Dev Biol (1988) 1.26
Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem Biol (1999) 1.26
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer (2001) 1.24
Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem (1991) 1.23
Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem Pharmacol (1996) 1.21
Transcriptional inactivation of c-myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells. Mol Cell Biol (1987) 1.20
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest (1998) 1.20
Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res (2000) 1.19
Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions. FEBS Lett (1994) 1.18
Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease. Bioorg Med Chem Lett (2009) 1.18
A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene (2010) 1.17
Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest (1997) 1.16
Histone acetylation and the cell-cycle in cancer. Front Biosci (2001) 1.16
Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res (1997) 1.15
Expression of the gastrin-releasing peptide gene in human small cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs. J Biol Chem (1986) 1.15
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood (1996) 1.15
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem (2000) 1.13
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res (2000) 1.13
A protein expression database for the molecular pharmacology of cancer. Electrophoresis (1997) 1.13
Targeted toxins. Clin Cancer Res (2000) 1.12
Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res (1999) 1.12